BioMime Vs. Xience Randomised Control Clinical Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 256 participants.

Also called NCT02112981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02112981
  • EudraCT 2013-005353-67
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Brazil, Czechia, Latvia, Netherlands, North Macedonia, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02112981. Randomized; no masking; primary purpose treatment. Start 2014-11-05 (actual); primary completion 2017-09-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BioMime Vs. Xience Randomised Control Clinical Study
Acronym
meriT-V
Intervention (Device)
Sirolimus Eluting Coronary Stent
Intervention (Device)
Everolimus-eluting Coronary stent
Lead sponsor
Meril Life Sciences Pvt. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02112981
Content hash
297aedd4742197b08c058eb92333647f8ae1e6c7eb84ed4d09125022c881ca9f